Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTR1E | P28566 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003856 | 0.86 | TSHR (0.53) | TSHRMAPTMEN1KMT2AHTT | |
| SCHEMBL1013113 | 0.86 | MAPT (0.50) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL20042905 | 0.86 | TSHR (0.53) | TSHRMAPTMEN1KMT2AHTT | |
| SCHEMBL2282127 | 0.85 | MAPT (0.52) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL1029279 | 0.84 | PDE4A (0.59) | TSHRHTTLMNAALDH1A1TTR | |
| SCHEMBL9841154 | 0.83 | TSHR (0.53) | TSHRMEN1KMT2AHTTLMNA | |
| SCHEMBL403840 | 0.83 | RORC (0.56) | TSHRMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL25212586 | 0.82 | MAPT (0.52) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL2016215 | 0.82 | TTR (0.49) | TSHRMEN1KMT2AHTTLMNA | |
| SCHEMBL11576422 | 0.81 | TSHR (0.52) | TSHRMEN1KMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-20250026762-A1 | FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4441034-A1 | FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023101895-A1 | FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | US | disclosed |
| WO-2018066718-A1 | THERAPEUTIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-12 | — | — | WO | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| EP-2271643-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039889-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | TSHR 3071/4885MAPT 1092/4885MEN1 2901/4885 |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | TSHR 3584/4885MAPT 2596/4885MEN1 1941/4885 |
| US-20250026762-A1 | FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, UGCG | TSHR 3857/4885MAPT 1472/4885MEN1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.